May 5th, 2025 1st Quarter 2025 Financial Results & Corporate Update This Slide Presentation Includes Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech's expected revenues and net profit/(loss) related to sales of BioNTech's COVID-19 vaccine, referred to as COMIRNATY where approved for use under full or conditional marketing auth ...

BioNTech (BNTX) Q1 2025 Earnings Call May 05, 2025 08:00 AM ET Company Participants Michael Horowicz - Director - IRUgur Sahin - Co-Founder, CEO & Chair of the Management BoardÖzlem Türeci - Co-Founder, Chief Medical Officer & Member of Management BoardJens Holstein - CFORyan Richardson - Chief Strategy OfficerAkash Tewari - Managing DirectorCory Kasimov - Senior Managing DirectorMohit Bansal - Managing DirectorKarina Rabayeva - VP - Biotech Equity ResearchHarry Gillis - Vice President - Pharmaceuticals Equ ...

BioNTech (BNTX) Q1 2025 Earnings Call May 05, 2025 08:00 AM ET Speaker0 Welcome to BioNTech's First Quarter twenty twenty five Earnings Call. I would like to hand the call over to Michael Horowitz, Director of Investor Relations. Please go ahead. Speaker1 Thank you. Good morning and good afternoon. Thank you for joining BioNTech's First Quarter twenty twenty five Earnings Call. As a reminder, the slides we will be using during this call and the corresponding press release we issued this morning can be found ...

Core Insights - BioNTech reported a net loss of €415.8 million for Q1 2025, compared to a net loss of €315.1 million in Q1 2024, indicating a significant increase in losses year-over-year [3][7][10] - Revenues for Q1 2025 were €182.8 million, a decrease from €187.6 million in the same period last year, primarily driven by COVID-19 vaccine collaboration [3][10] - The company maintains a strong financial position with €15.9 billion in cash, cash equivalents, and security investments as of March 31, 2025 [8][9] Financial Review - Revenues for Q1 2025: €182.8 million, down from €187.6 million in Q1 2024 [3] - Net loss for Q1 2025: €415.8 million, compared to €315.1 million in Q1 2024 [7] - Basic and diluted loss per share: €1.73 for Q1 2025, up from €1.31 in Q1 2024 [9] - Cost of sales increased to €83.8 million in Q1 2025 from €59.1 million in Q1 2024 [4] - R&D expenses rose to €525.6 million in Q1 2025 from €507.5 million in Q1 2024, driven by late-stage clinical studies [5] - SG&A expenses decreased to €120.6 million in Q1 2025 from €132.6 million in Q1 2024 [6] Corporate Strategy and Outlook - BioNTech is focusing on advancing its oncology pipeline, particularly the bispecific antibody candidate BNT327 and mRNA cancer immunotherapies [8][17] - The company confirmed its financial guidance for 2025, expecting revenues between €1,700 million and €2,200 million, with a similar revenue phasing to 2024 [10][11] - Planned R&D expenses for 2025 are estimated between €2,600 million and €2,800 million, with SG&A expenses projected at €650 million to €750 million [11] Clinical Development Updates - BioNTech presented multiple clinical updates for its oncology pipeline, including promising data for BNT327 in combination with antibody-drug conjugates [8][19] - Preliminary data from ongoing trials indicate anti-tumor activity and manageable safety profiles for BNT327 in various cancer indications [18][19] - The company is preparing for the 2025/2026 season variant-adapted COVID-19 vaccine [8][26] Management Changes - Ramón Zapata-Gomez has been appointed as the new CFO effective July 1, 2025, succeeding Jens Holstein [26]

本文字数：702，阅读时长大约1分钟 据央视新闻报道，5月4日至5日，中国人民银行行长潘功胜率团赴意大利米兰出席东盟与中日韩 （10+3）财长和央行行长会，并作为10+3财金合作机制联合主席主持相关讨论，与会议各方就美关 税政策对全球和区域宏观经济形势造成的影响、完善清迈倡议多边化（CMIM）机制和10+3宏观经 济研究办公室（AMRO）等议题深入交换了意见，并推动各方在深化区域内政策协调和加强区域金 融安全网等领域达成一系列共识。 会议一致通过了在清迈倡议多边化下新设以人民币等可自由使用 货币出资的快速融资工具相关安排，并明确了清迈倡议机制化下一步讨论方向。 2025.05. 05 中日韩三方同期举行了财长和央行行长会，就经济形势和区域内财金合作交流意见。潘功胜 呼吁区 域国家团结一致应对美关税冲击，介绍了中方相关宏观经济政策。 潘功胜还在会间与日本财长加藤 正信、韩国央行行长李昌镛、马来西亚央行行长拉希德进行双边会谈，就全球不确定性对各国影响交 换了意见。 微信编辑 | 七三 多地宣布发钱奖励结婚！ 潘功胜指出，当前单边主义正冲击以规则为基础的多边经贸体系和国际治理体系，全球经济不确定性 上升，10+3区 ...

中国人民银行行长潘功胜出席并主持东盟与中日韩财长和央行行长会 责编：叶舒筠 校对： 吕久彪 版权声明 证券时报各平台所有原创内容，未经书面授权，任何单位及个人不得转载。我社保留追 究相关 行 为主体 法律责任的权利。 转载与合作可联系证券时报小助理，微信ID：SecuritiesTimes 2025年5月4日至5日，中国人民银行行长潘功胜率团赴意大利米兰出席东盟与中日韩（10+3）财长和央行行长 会，并作为10+3财金合作机制联合主席主持相关讨论，与会议各方就美关税政策对全球和区域宏观经济形势 造成的影响、完善清迈倡议多边化（CMIM）机制和10+3宏观经济研究办公室（AMRO）等议题深入交换了意 见，并推动各方在深化区域内政策协调和加强区域金融安全网等领域达成一系列共识。会议一致通过了在清迈 倡议多边化下新设以人民币等可自由使用货币出资的快速融资工具相关安排，并明确了清迈倡议机制化下一步 讨论方向。 潘功胜指出，当前单边主义正冲击以规则为基础的多边经贸体系和国际治理体系，全球经济不确定性上升， 10+3区域面临的经济和金融风险亦显著上升。在此背景下，进一步完善清迈倡议机制、强化本区域金融安全 网至关重要。引 ...

中国人民银行行长潘功胜出席并主持东盟与中日韩财长和央行行长会 中日韩三方同期举行了财长和央行行长会，就经济形势和区域内财金合作交流意见。潘功胜呼吁区域国家团结 一致应对美关税冲击，介绍了中方相关宏观经济政策。潘功胜还在会间与日本财长加藤正信、韩国央行行长李 昌镛、马来西亚央行行长拉希德进行双边会谈，就全球不确定性对各国影响交换了意见。 会后，中国和马来西亚作为2025年10+3联合主席召开了联合记者会，潘功胜代表中国人民银行介绍了会议达 成的合作成果。 2025年5月4日至5日，中国人民银行行长潘功胜率团赴意大利米兰出席东盟与中日韩（10+3）财长和央行行长 会，并作为10+3财金合作机制联合主席主持相关讨论，与会议各方就美关税政策对全球和区域宏观经济形势 造成的影响、完善清迈倡议多边化（CMIM）机制和10+3宏观经济研究办公室（AMRO）等议题深入交换了意 见，并推动各方在深化区域内政策协调和加强区域金融安全网等领域达成一系列共识。会议一致通过了在清迈 倡议多边化下新设以人民币等可自由使用货币出资的快速融资工具相关安排，并明确了清迈倡议机制化下一步 讨论方向。 潘功胜指出，当前单边主义正冲击以规则为基础的 ...

Core Insights - IBA has launched the QUASAR GRID Advantage Image Distortion Analysis System, enhancing quality assurance in MR-guided radiation therapy and MR simulation planning [1][2]. Company Overview - IBA (Ion Beam Applications S.A.) is a leader in particle accelerator technology and a major provider of dosimetry and quality assurance solutions, employing approximately 2,100 people globally [6][7]. - The company is recognized for its advanced proton therapy equipment and services, which are considered the most sophisticated form of radiation therapy available today [6]. Product Features - The GRID Advantage system is designed for facilities needing precise MR distortion analysis for stereotactic planning, ensuring geometric fidelity in MR images [2][3]. - It offers automated analysis through user-friendly software and includes versatile multi-use solutions with various frame adapters or frameless options [2]. Industry Context - The use of MR in radiation therapy is increasing due to its superior soft tissue contrast without ionizing radiation, making precise imaging critical for effective tumor targeting and protection of healthy tissue [3]. - The introduction of robust QA tools like GRID Advantage is essential to maintain image fidelity and enhance clinical confidence in treatment accuracy [3][4]. Expert Commentary - Industry experts highlight that the GRID Advantage represents a significant advancement in quality assurance for Gamma Knife radiosurgery, emphasizing the importance of geometric distortion QA in radiation therapy workflows [4].

Core Insights - The combination of Mixed Reality (MR) and Artificial Intelligence (AI) is driving transformative changes across various industries, enhancing efficiency and creating new business models and service experiences [1][3][7] Manufacturing Industry - MR and AI are revolutionizing smart manufacturing by improving product design, production monitoring, quality control, and equipment maintenance, leading to smarter, more efficient, and precise operations [1][3] - In product design, MR provides an immersive virtual environment for designers to interact with 3D models, while AI uses big data analysis to recommend optimal design solutions, enhancing design quality and production efficiency [1][3] Retail Industry - The integration of MR and AI in retail creates personalized shopping experiences, improving customer satisfaction and optimizing store operations [3][7] - AI analyzes consumer data to predict future needs and provide personalized recommendations, increasing sales conversion rates and optimizing inventory management [3][4] - MR technology allows customers to virtually try on products, enhancing their purchasing confidence and efficiency [4][5] Healthcare Industry - MR and AI are transforming medical diagnostics, treatment planning, and patient management by providing new solutions that enhance diagnostic accuracy and treatment effectiveness [7][8] - AI assists in disease diagnosis by analyzing medical imaging data, while MR offers visual aids for doctors to better understand patient anatomy during procedures [7][8] Education Industry - The combination of MR and AI addresses the need for personalized learning and immersive experiences in education, particularly in training and skill acquisition [8][9] - AI customizes learning plans based on student performance, while MR provides practical simulations for hands-on training without real-world risks [8][9] Automotive Industry - MR and AI are crucial for the development of safe and efficient autonomous driving systems, with AI analyzing traffic conditions and MR enhancing driver experience through real-time information overlays [9][10] Financial Industry - The integration of MR and AI in finance offers personalized services and enhances risk management and marketing strategies [10][11] - AI analyzes customer data to provide tailored financial products, while MR visualizes risk data for better decision-making [11][12] Logistics and Supply Chain Management - MR and AI provide innovative solutions for logistics and supply chain management, addressing challenges like information asymmetry and inefficiency [12][13] - AI optimizes transportation routes and inventory management, while MR offers real-time visibility into logistics processes, improving operational efficiency [12][13]

Agreement maintains reliable electricity supply in Baltimore through May 2029HOUSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Talen Energy Corporation (“Talen”) (NASDAQ: TLN) announced today that the Federal Energy Regulatory Commission (the “FERC”) has approved the terms under which Talen will operate units at its Brandon Shores and H.A. Wagner power plants until May 31, 2029, beyond their scheduled May 31, 2025 retirement dates. Talen, PJM Interconnection, L.L.C. (“PJM”), and a broad coalition of the Maryland Pu ...